Постменопаузальный остеопороз: патофизиология, клинические проявления, подходы к лечению
- Авторы: Кузнецова ИВ1, Успенская ЮБ2
-
Учреждения:
- ММА им. И.М.Сеченова
- НИЦ ММА им. И.М.Сеченова
- Выпуск: Том 10, № 4 (2008)
- Страницы: 54-59
- Раздел: Статьи
- URL: https://ogarev-online.ru/2079-5831/article/view/27961
- ID: 27961
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
И В Кузнецова
ММА им. И.М.СеченоваКафедра акушерства и гинекологии №1 лечебного факультета
Ю Б Успенская
НИЦ ММА им. И.М.Сеченова
Список литературы
- Сметник В.П. Постменопаузальный остеопороз. Медицина климактерия. Ярославль: ООО "Изд - во Литтерра", 2006; 656–86.
- Black D.M, Cummings S.R, Karpf D.B et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41.
- Bishop N.J, Nincovic M, Alexander G.J et al. Changes in calcium homeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre - operatively. Clin Sci 1999; 97: 157–163.
- Bonabello A, Galmozzi M.R, Bruzzese T, Zara G.P. Analgetic effect of biphosphonates in mice. Pain 2001; 91: 269–75.
- Bone H.G, Greenspan S.L, Mc Keever C, Bell N et al. Alendronate and estrogen effects in postmenopausal women with low dose bone mineral density. J Clin Endocrinol Metab 2000; 85: 720–6.
- Carr D.B, Goudas L.C. Acute pain. Lancet 1999; 353: 2051–8.
- Cauley J.A, Thompson D.E, Ensrud K.S et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556–61.
- Cranney A, Wells G, Willan A et al. IX: Summary of meta - analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–8.
- Center J.R, Nguen T.V, Schneider D et al. Mortality after all mayor types of osteoporetic fracture in men and women: an observational study. Lancet 1999; 353: 878–92.
- Cummings S.R, Melton L.I. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–7.
- Downs Jr.R.W, Bell N.H, Ettinger M.P et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 1783–8.
- Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of biphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78: 157–69.
- Garnero P, Shih W.J, Gineyts E et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700.
- Geza B. Vizsgalatok a genericus alendronat natriummal, a Sedronnal. Praxis 2008; 17: 731–41.
- Greenspan S, Field-Munves E, Tonino R et al. Tolerability of once - weekly alendronate in patients with osteoporosis: a randomized, double - blind, placebo - controlled study. Mayo Clin Proc 2002; 77: 1044–52.
- Hodgson S.F, Watts N.B, Belezikian J.P et al. American Assotiation of Clinical Endocrinologist medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544–64.
- Hosking D, Chilvers C.E.D, Christiansen C et al. Prevention of bone loss with alendronate in postmenopaus
Дополнительные файлы
